In the current study, we demonstrate that the loss of PP2A function through genetic manipulation or drug treatment makes a variety of mouse immune tolerance tumour models sensitive to ICB, and it has been further confirmed by using human cancer cell lines and human CRC tissue arrays. The gene discussed is PTPA; the disease is cancer.